288 related articles for article (PubMed ID: 33131269)
1. Different iron-handling in inflamed small and large cholangiocytes and in small and large-duct type intrahepatic cholangiocarcinoma.
Mancinelli R; Cutone A; Rosa L; Lepanto MS; Onori P; Pannarale L; Franchitto A; Gaudio E; Valenti P
Eur J Histochem; 2020 Oct; 64(4):. PubMed ID: 33131269
[TBL] [Abstract][Full Text] [Related]
2. Dysregulation of Iron Metabolism in Cholangiocarcinoma Stem-like Cells.
Raggi C; Gammella E; Correnti M; Buratti P; Forti E; Andersen JB; Alpini G; Glaser S; Alvaro D; Invernizzi P; Cairo G; Recalcati S
Sci Rep; 2017 Dec; 7(1):17667. PubMed ID: 29247214
[TBL] [Abstract][Full Text] [Related]
3. An immunostaining panel of C-reactive protein, N-cadherin, and S100 calcium binding protein P is useful for intrahepatic cholangiocarcinoma subtyping.
Akita M; Sawada R; Komatsu M; Suleman N; Itoh T; Ajiki T; Heaton N; Fukumoto T; Zen Y
Hum Pathol; 2021 Mar; 109():45-52. PubMed ID: 33321161
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor-like domain multiple 7 (EGFL7): Expression and possible effect on biliary epithelium growth in cholangiocarcinoma.
Mammola CL; Vetuschi A; Pannarale L; Sferra R; Mancinelli R
Eur J Histochem; 2018 Nov; 62(4):. PubMed ID: 30504933
[TBL] [Abstract][Full Text] [Related]
5. Intrahepatic cholangiocarcinoma: typical features, uncommon variants, and controversial related entities.
Zen Y
Hum Pathol; 2023 Feb; 132():197-207. PubMed ID: 35697170
[TBL] [Abstract][Full Text] [Related]
6. Cholangiocytes in the pathogenesis of primary sclerosing cholangitis and development of cholangiocarcinoma.
Chung BK; Karlsen TH; Folseraas T
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1390-1400. PubMed ID: 28844951
[TBL] [Abstract][Full Text] [Related]
7. Bile duct adenoma may be a precursor lesion of small duct type intrahepatic cholangiocarcinoma.
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2021 Jan; 78(2):310-320. PubMed ID: 33405289
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression.
Erice O; Labiano I; Arbelaiz A; Santos-Laso A; Munoz-Garrido P; Jimenez-Agüero R; Olaizola P; Caro-Maldonado A; Martín-Martín N; Carracedo A; Lozano E; Marin JJ; O'Rourke CJ; Andersen JB; Llop J; Gómez-Vallejo V; Padro D; Martin A; Marzioni M; Adorini L; Trauner M; Bujanda L; Perugorria MJ; Banales JM
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1335-1344. PubMed ID: 28916388
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of PDZK1IP1, EEF1A2 and RPL41 genes in intrahepatic cholangiocarcinoma.
Yang G; Zong H
Mol Med Rep; 2016 Jun; 13(6):4786-90. PubMed ID: 27082702
[TBL] [Abstract][Full Text] [Related]
10. Quantitative Proteomics Reveals Down-Regulated Glycolysis/Gluconeogenesis in the Large-Duct Type Intrahepatic Cholangiocarcinoma.
Guo Y; Li Q; Ren W; Wu H; Wang C; Li X; Xue B; Qiu Y; Zhang J; Chen J; Fang L
J Proteome Res; 2022 Oct; 21(10):2504-2514. PubMed ID: 36066509
[TBL] [Abstract][Full Text] [Related]
11. Cholangiocarcinoma in Germany: Epidemiologic trends and impact of misclassification.
Walter D; Ferstl P; Waidmann O; Trojan J; Hartmann S; Schnitzbauer AA; Zeuzem S; Kraywinkel K
Liver Int; 2019 Feb; 39(2):316-323. PubMed ID: 30176117
[TBL] [Abstract][Full Text] [Related]
12. Nestin may be a candidate marker for differential diagnosis between small duct type and large duct type intrahepatic cholangiocarcinomas.
Sasaki M; Sato Y; Nakanuma Y
Pathol Res Pract; 2024 Jan; 253():155061. PubMed ID: 38154357
[TBL] [Abstract][Full Text] [Related]
13. YAP1 activation and Hippo pathway signaling in the pathogenesis and treatment of intrahepatic cholangiocarcinoma.
Ko S; Kim M; Molina L; Sirica AE; Monga SP
Adv Cancer Res; 2022; 156():283-317. PubMed ID: 35961703
[TBL] [Abstract][Full Text] [Related]
14. Pathologic classification of cholangiocarcinoma: New concepts.
Nakanuma Y; Kakuda Y
Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):277-93. PubMed ID: 25966428
[TBL] [Abstract][Full Text] [Related]
15. Preoperative subcategorization based on magnetic resonance imaging in intrahepatic cholangiocarcinoma.
Xiao Y; Zhou C; Ni X; Huang P; Wu F; Yang C; Zeng M
Cancer Imaging; 2023 Feb; 23(1):15. PubMed ID: 36782276
[TBL] [Abstract][Full Text] [Related]
16. SUOX and GLUT1 are biomarkers for the prognosis in large duct type intrahepatic cholangiocarcinoma.
Kinjo Y; Naito Y; Akiba J; Sadashima E; Nakayama M; Tanigawa M; Hisaka T; Okabe Y; Yano H
Hum Pathol; 2022 Oct; 128():11-19. PubMed ID: 35764144
[TBL] [Abstract][Full Text] [Related]
17. A Mouse Model of Cholangiocarcinoma Uncovers a Role for Tensin-4 in Tumor Progression.
Di-Luoffo M; Pirenne S; Saandi T; Loriot A; Gérard C; Dauguet N; Manzano-Núñez F; Alves Souza Carvalhais N; Lamoline F; Cordi S; Konobrocka K; De Greef V; Komuta M; Halder G; Jacquemin P; Lemaigre FP
Hepatology; 2021 Sep; 74(3):1445-1460. PubMed ID: 33768568
[TBL] [Abstract][Full Text] [Related]
18. Utility of DNA flow cytometry in distinguishing between malignant and benign intrahepatic biliary lesions.
Wen KW; Rabinovitch PS; Wang D; Mattis AN; Ferrell LD; Choi WT
Virchows Arch; 2020 Oct; 477(4):527-534. PubMed ID: 32296928
[TBL] [Abstract][Full Text] [Related]
19. Clonorchis sinensis excretory-secretory products increase malignant characteristics of cholangiocarcinoma cells in three-dimensional co-culture with biliary ductal plates.
Won J; Cho Y; Lee D; Jeon BY; Ju JW; Chung S; Pak JH
PLoS Pathog; 2019 May; 15(5):e1007818. PubMed ID: 31121000
[TBL] [Abstract][Full Text] [Related]
20. Keratin 19-expressing hepatocellular carcinoma and small-duct type intrahepatic cholangiocarcinoma show a similar postoperative clinical course but have distinct genetic features.
Akita M; Ajiki T; Fukumoto T; Itoh T; Zen Y
Histopathology; 2019 Sep; 75(3):385-393. PubMed ID: 31017316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
